<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431457</url>
  </required_header>
  <id_info>
    <org_study_id>2007/005</org_study_id>
    <nct_id>NCT00431457</nct_id>
  </id_info>
  <brief_title>Controlled Randomized Stimulation Versus Resection (CoRaStiR)</brief_title>
  <official_title>Prospective Randomized Controlled Study of Neurostimulation in the Medial Temporal Lobe for Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Stimulation Versus Resection (CoRaStiR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be prospectively randomized to 3 different treatment arms:&#xD;
&#xD;
        -  Treatment group 1: patients who undergo medial temporal lobe resection&#xD;
&#xD;
        -  Treatment group 2: patients who receive immediate hippocampal neurostimulation&#xD;
&#xD;
        -  Treatment group 3: patients who are implanted with an intracranial electrode but in whom&#xD;
           hippocampal neurostimulation is delayed for 6 months.&#xD;
&#xD;
      Twelve months after inclusion unblinding will occur. Patients in group 2 and 3 will have the&#xD;
      option to choose between continuing neurostimulation treatment or resective surgery.&#xD;
&#xD;
      Study visits will occur every 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether stimulation and/or resection produces a reduction in mean monthly seizure frequency that is greater than in the control group over 6 months of follow-up.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess whether stimulation produces a reduction in mean monthly seizure frequency that is comparable to resection at 6 and 12 months of follow-up.</measure>
    <time_frame>at 6 and 12 months of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess whether stimulation yields better neuropsychological outcome compared to resection at 12 months of follow-up.</measure>
    <time_frame>at 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>responder rates during 3 month intervals</measure>
    <time_frame>3 months intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean seizure free interval during 3 month intervals</measure>
    <time_frame>3 month intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seizure severity and seizure type during 3-month intervals</measure>
    <time_frame>3-month intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life: changes in QOLIE 89 score at 6 and 12 months</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mood assessment: changes in Beck depression scale scores at 6 and 12 month</measure>
    <time_frame>at 6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Objectives:</measure>
    <time_frame>during twelve months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative and postoperative complications and long-term side effects</measure>
    <time_frame>during twelve months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Implantation intracranial electrode with immediate stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Implantation intracranial electrode without stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resective surgery: amygddohyppocampertomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of an intracranial electrode</intervention_name>
    <description>Implantation of an intracranial electrode will be followed.</description>
    <arm_group_label>Implantation intracranial electrode with immediate stimulation</arm_group_label>
    <arm_group_label>Implantation intracranial electrode without stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>amygddohyppocampertomy</intervention_name>
    <description>Resective surgery</description>
    <arm_group_label>Resective surgery: amygddohyppocampertomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presurgical candidates with pharmacoresistant partial seizures despite optimal medical&#xD;
             treatment and history of temporal lobe epilepsy&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  TIQ &gt; 80&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Average of 2 partial seizures per month during a baseline of 3 months. Recording of&#xD;
             seizures must have been done in a prospective manner using standard seizure diaries.&#xD;
&#xD;
          -  Able to adequately report seizure frequencies using standard seizure diaries&#xD;
&#xD;
          -  Video-EEG characteristics showing temporal lobe seizure onset (left-sided or&#xD;
             right-sided seizure onset) in at least one recorded habitual seizure&#xD;
&#xD;
          -  Presence of a structural abnormality in the medial temporal lobe, suggestive of&#xD;
             hippocampal sclerosis as evidenced by optimum MRI&#xD;
&#xD;
          -  Women of child-bearing age will be required to use a reliable method of contraception&#xD;
             during the study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extratemporal epilepsy; multifocal epilepsy; evidence of bilateral medial temporal&#xD;
             lobe epilepsy&#xD;
&#xD;
          -  MR evidence of potentially epileptogenic lesions outside the medial temporal lobe such&#xD;
             as dysplasias, tumours or cavernomas&#xD;
&#xD;
          -  Prior resective intracranial surgery&#xD;
&#xD;
          -  Patients who are candidates for invasive video-EEG recording or have previously been&#xD;
             investigated with invasive video-EEG recording&#xD;
&#xD;
          -  Patients who previously underwent any other type of neurostimulation for treating&#xD;
             epilepsy&#xD;
&#xD;
          -  Patients who are unable to fill in questionnaires and comply with protocol&#xD;
             requirements&#xD;
&#xD;
          -  Progressive neurological or medical conditions&#xD;
&#xD;
          -  Medical or psychiatric conditions precluding surgery or compliance&#xD;
&#xD;
          -  Patients taking antidepressant medication&#xD;
&#xD;
          -  Pregnancy at study onset&#xD;
&#xD;
          -  Previous (within the last 3 months), ongoing or planned participation in other&#xD;
             treatment study protocols for epilepsy&#xD;
&#xD;
          -  Contraindication for intracranial surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Boon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristl Vonck, MD</last_name>
    <phone>+ 32 9 332.64.88</phone>
    <email>kristl.vonck@UGent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristl Vonck, MD</last_name>
      <phone>+ 32 9 332.64.88</phone>
      <email>kristl.vonck@UGent.be</email>
    </contact>
    <investigator>
      <last_name>Kristl Vonck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKB Universit√§tsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Malter, MD</last_name>
      <phone>+49 228 287 15 748</phone>
      <email>michael.malter@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Michael Malter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schulze-Bonhage, PhD</last_name>
      <phone>+49 761 270 53 66</phone>
      <email>andreas.schulze-bonhage@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Schulze-Bonhage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2007</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

